论文信息 - Immune-Related Adverse Events-A Novel Prediction of Nivolumab Efficacy?-Reply. - 字舞流文

Immune-Related Adverse Events-A Novel Prediction of Nivolumab Efficacy?-Reply.

K. Nakagawa | H. Hayashi | K. Haratani

[1] Kaoru Tanaka,et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer , 2017, JAMA oncology.

[2] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.